SGHT vs. SRDX, BVS, SDC, IRMD, SIBN, ATRC, AORT, CATX, SILK, and ATRI
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include Surmodics (SRDX), Bioventus (BVS), SmileDirectClub (SDC), Iradimed (IRMD), SI-BONE (SIBN), AtriCure (ATRC), Artivion (AORT), Perspective Therapeutics (CATX), Silk Road Medical (SILK), and Atrion (ATRI). These companies are all part of the "medical" sector.
Surmodics (NASDAQ:SRDX) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Surmodics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.73, meaning that its stock price is 173% more volatile than the S&P 500.
Surmodics has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.
Surmodics currently has a consensus target price of $57.00, indicating a potential upside of 64.88%. Sight Sciences has a consensus target price of $4.70, indicating a potential downside of 19.52%. Given Sight Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Surmodics is more favorable than Sight Sciences.
In the previous week, Surmodics had 12 more articles in the media than Sight Sciences. MarketBeat recorded 16 mentions for Surmodics and 4 mentions for Sight Sciences. Surmodics' average media sentiment score of 1.03 beat Sight Sciences' score of 0.70 indicating that Sight Sciences is being referred to more favorably in the news media.
Surmodics received 322 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 67.13% of users gave Surmodics an outperform vote while only 31.91% of users gave Sight Sciences an outperform vote.
96.6% of Surmodics shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 8.9% of Surmodics shares are owned by insiders. Comparatively, 28.9% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Surmodics has a net margin of 9.44% compared to Surmodics' net margin of -67.18%. Sight Sciences' return on equity of 13.30% beat Surmodics' return on equity.
Summary
Surmodics beats Sight Sciences on 15 of the 18 factors compared between the two stocks.
Get Sight Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
